Kaiser Health News/NPR Examine U.S. FDA’s Priority Review Voucher Program

Kaiser Health News/NPR: Are Golden Tickets That Speed Drugs Through FDA Worthwhile? “…Members of Congress, the pharmaceutical industry, and rare disease advocates have passionately supported [priority review] vouchers as a way to spur development of drugs for rare and neglected diseases. But skeptics, including FDA officials and some academics, have questioned whether the program is…More

See the original post here:
Kaiser Health News/NPR Examine U.S. FDA’s Priority Review Voucher Program